<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208506</url>
  </required_header>
  <id_info>
    <org_study_id>NN8828-3837</org_study_id>
    <secondary_id>2010-018347-33</secondary_id>
    <secondary_id>U1111-1116-2585</secondary_id>
    <nct_id>NCT01208506</nct_id>
  </id_info>
  <brief_title>First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,
      tolerability, pharmacokinetic (the effect of the body on the investigated drug),
      pharmacodynamic biomarkers (biomarkers related to anti-IL-21 expected mode of action) and
      signs of clinical efficacy of increasing single doses, at 9 i.v. (into the vein) dose levels
      in Healthy Subjects , at 3 i.v. dose levels in subjects with rheumatoid arthritis (RA) and at
      3 s.c. dose levels in Healthy Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum level of free IL-21 and maximum level of bound IL-21 in peripheral blood</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) in subjects with RA</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.</description>
    <arm_group_label>Dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.</description>
    <arm_group_label>Dose level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.</description>
    <arm_group_label>Dose level 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.</description>
    <arm_group_label>Dose level 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single dose of NNC0114-0000-0005 placebo.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_label>Dose level 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all subjects the following applies:

          -  Male subjects, if not sterilized, must be using two acceptable methods of
             contraception (e.g., spermicidal gel plus condom) for the entire duration of the trial
             corresponding to up to three months following trial drug administration. Male subjects
             must also agree to refrain from sperm donation from screening (trial start) until 120
             days beyond trial drug administration

          -  For healthy subjects (HS) the following additional criteria applies:

          -  Male subjects, aged between 18 and 60 years (both inclusive) and in good health, as
             determined by past medical history, physical examination, vital signs,
             (electrocardiogram) ECG, and laboratory tests at screening (trial start)

          -  For subjects with rheumatoid arthritis (RA) the following additional criteria applies:

          -  Diagnosed with RA at least 3 months prior to trial drug administration

          -  Active RA, characterised by a Disease Activity Score 28 (DAS28)-C-reactive protein
             (CRP) greater than 3.2

          -  Effective methods of contraception

          -  Male and female subjects aged greater and equal to 18 and greater and equal to 75
             years

          -  Females must be post-menopausal or surgically sterile (post-menopausal for at least 1
             year). If female of child-bearing potential must be willing to use highly effective
             method of birth control during the trial until their final visit

          -  Methotrexate treatment (MTX) treatment for at least 12 weeks at a stable dose (dose at
             least 7.5 mg/week and maximum 25 mg/week inclusive) for at least 4 weeks prior to
             trial product administration

          -  Concomitant medication according to specific list

        Exclusion Criteria:

          -  For all subjects the following applies:

          -  Body mass index (BMI) between 20.0-38.0 kg/m2 (both inclusive)

          -  Females with a positive pregnancy test

          -  History of regular alcohol consumption exceeding 14 drinks per week for females or 21
             drinks per week for men

          -  Donation or loss of at least 400 mL of blood within 8 weeks prior to trial product
             administration

          -  For healthy subjects (HS) the following additional criteria applies:

          -  Body weight greater than 110.0 kg

          -  For subjects with rheumatoid arthritis (RA) the following additional criteria applies:

          -  Chronic inflammatory autoimmune disease other than RA (except secondary Sj√∂gren's
             syndrome or stable hypothyroidism)

          -  History of or current inflammatory joint disease other than RA such as gout (crystal
             proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive
             arthritis or Lyme disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>First in human study with recombinant anti-IL-21 monoclonal antibody in healthy subjects and patients with rheumatoid arthritis. Arthritis and Rheumatism 2012; 64 (10 (supplement)): Abstract 1279</citation>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

